Mallinckrodt Pays $117M for This Bay Area Biotech and Its Failed Liver Drug Post author:Sam Post published:November 1, 2017 Post category:BioPharma Mallinckrodt has agreed to buy Ocera Therapeutics in a deal that could hit $117M. Source: BioSpace You Might Also Like Rumor Alert: Novartis AG In Talks to Buy NASH Biotech GENFIT March 2, 2017 Bristol-Myers Squibb Could Finally Go on the Market; Rumored Suitors Include Gilead, Pfizer, Novartis AG and Roche February 13, 2017 Adocia Announces First Quarter 2017 Financial Results April 17, 2017
Bristol-Myers Squibb Could Finally Go on the Market; Rumored Suitors Include Gilead, Pfizer, Novartis AG and Roche February 13, 2017
